A PYMNTS Company

Germany/US: Sanofi gets US, German nods for Ablynx deal

By  |  March 1, 2018

On Thursday, March 1, Sanofi announced that it has received antitrust clearances in the US and Germany in connection with its proposed acquisition of Ablynx.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Sanofi said that a waiting period for its proposed acquisition of Ablynx had expired without objections being raised. Under the US Hart-Scott-Rodino Antitrust Improvements Act, parties to certain transactions must submit notification to the country’s Federal Trade Commission and Department of Justice and wait before the transaction can be completed.

    The proposed acquisition has also been cleared by the Federal Cartel Office (FCO) of Germany, the French pharmaceutical company said.

    With the expiration of the waiting period and the FCO clearance, “the condition to the offers relating to antitrust approvals has been satisfied,” Sanofi said.

    Full Content: Market Watch

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.